GlassScriptPhysician profile
Raman Battish
NPI 1770791923
$8,489.27
in general payments reported to CMS, 2019-2025
30 companies · $381 in 2025
The $381 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,301 · 2020: $55.40 · 2021: $1,150 · 2022: $332 · 2023: $486 · 2024: $785 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,401 · Consulting Fee: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,401.42 |
| Consulting Fee | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $5,580.14 | 2019-2024 | Exalt Model D |
| Tersera Therapeutics LLC | $900.00 | 2021 | |
| Abbvie INC. | $434.07 | 2022-2025 | Linzess, Creon, Viberzi |
| US Endoscopy | $250.00 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $242.88 | 2022-2024 | Trulance, Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $200.92 | 2022-2025 | Entyvio, Eohilia |
| Conmed Corporation | $98.61 | 2022 | |
| Genzyme Corporation | $97.02 | 2022-2024 | |
| Janssen Biotech, INC. | $93.62 | 2022-2024 | Stelara, Tremfya, Simponi |
| Regeneron Healthcare Solutions, INC. | $65.12 | 2019-2025 | Dupixent |
| Qol Medical, LLC | $63.81 | 2023-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $58.23 | 2024 | Omvoh |
| Evoke Pharma, INC. | $45.92 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $44.68 | 2020-2021 | |
| Ardelyx, INC. | $35.59 | 2023-2025 | Ibsrela |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $33.83 | 2019 | |
| Cook Medical LLC | $32.43 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $30.31 | 2024 | Voquezna |
| Novo Nordisk INC | $19.23 | 2025 | Wegovy |
| Ironwood Pharmaceuticals, INC | $17.00 | 2023 | Linzess |
| Ge Healthcare | $16.82 | 2025 | |
| Pfizer INC. | $16.82 | 2023 | |
| Amgen INC. | $16.22 | 2025 | Uplizna |
| Braintree Laboratories, INC. | $16.10 | 2024 | Sutab, Suflave |
| Celgene Corporation | $15.27 | 2023 | Zeposia |
| Merck Sharp & Dohme LLC | $14.72 | 2021 | |
| Ferring Pharmaceuticals INC. | $13.78 | 2022 | |
| Daiichi Sankyo INC. | $13.44 | 2023 | Injectafer |
| Tesaro, INC. | $12.69 | 2019 | |
| Erbe USA INC | $10.00 | 2023 | Erbe Vio3 Apc3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raman Battish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.